FdaApplication
NDA 208845
Identifiers
- fda_app_no: NDA208845
Properties
| Property | Value |
|---|---|
| applicant_name | PACIRA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2017-10-06 |
Revenue by product
ZILRETTA
| Period | Revenue |
|---|---|
| Q2 2026 | $32.6M |
| Q1 2026 | $26.8M |
| Q4 2025 | $33.0M |
| Q3 2025 | $29.0M |
| Q2 2025 | $31.3M |
| Q1 2025 | $23.3M |
| Q4 2024 | $33.1M |
| Q3 2024 | $28.4M |
| Q2 2024 | $30.7M |
| Q1 2024 | $25.8M |
| Q4 2023 | $28.7M |
| Q3 2023 | $28.8M |
| Q2 2023 | $29.3M |
| Q1 2023 | $24.3M |
| Q4 2022 | $28.0M |
| Q3 2022 | $26.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZILRETTA | TRIAMCINOLONE ACETONIDE | 32MG/VIAL | FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR |
1 product